FR2741342B1 - Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques - Google Patents

Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques

Info

Publication number
FR2741342B1
FR2741342B1 FR9513836A FR9513836A FR2741342B1 FR 2741342 B1 FR2741342 B1 FR 2741342B1 FR 9513836 A FR9513836 A FR 9513836A FR 9513836 A FR9513836 A FR 9513836A FR 2741342 B1 FR2741342 B1 FR 2741342B1
Authority
FR
France
Prior art keywords
phenylimidazolidines
hydroxylated
medicaments
application
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9513836A
Other languages
English (en)
Other versions
FR2741342A1 (fr
Inventor
Andre Claussner
Francois Goubet
Jean Georges Teutsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9513836A priority Critical patent/FR2741342B1/fr
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Priority to PCT/FR1996/001846 priority patent/WO1997019064A1/fr
Priority to US09/077,223 priority patent/US6087509A/en
Priority to JP9519453A priority patent/JP2000502053A/ja
Priority to AU76984/96A priority patent/AU7698496A/en
Priority to EP96939961A priority patent/EP0862559A1/fr
Priority to ZA9609820A priority patent/ZA969820B/xx
Publication of FR2741342A1 publication Critical patent/FR2741342A1/fr
Application granted granted Critical
Publication of FR2741342B1 publication Critical patent/FR2741342B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
FR9513836A 1995-11-22 1995-11-22 Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques Expired - Fee Related FR2741342B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR9513836A FR2741342B1 (fr) 1995-11-22 1995-11-22 Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
US09/077,223 US6087509A (en) 1995-11-22 1996-11-21 1-Imidazolidinyl-phenyls
JP9519453A JP2000502053A (ja) 1995-11-22 1996-11-21 新規な弗素化又はヒドロキシル化されたフェニルイミダゾリジン、それらの製造法及び中間体、薬剤としての用途、新規な用途並びに製薬組成物
AU76984/96A AU7698496A (en) 1995-11-22 1996-11-21 Novel fluorinated or hydroxylated phenylimidazolidines having anti-androgenic activity, method for preparing same, resulting intermediates, and pharmaceutical compositions
PCT/FR1996/001846 WO1997019064A1 (fr) 1995-11-22 1996-11-21 Nouvelles phenylimidazolidines fluorees ou hydroxylees ayant une activite anti-androgenique, leur procede de preparation, intermediaires obtenus et compositions pharmaceutiques
EP96939961A EP0862559A1 (fr) 1995-11-22 1996-11-21 Nouvelles phenylimidazolidines fluorees ou hydroxylees ayant une activite anti-androgenique, leur procede de preparation, intermediaires obtenus et compositions pharmaceutiques
ZA9609820A ZA969820B (en) 1995-11-22 1996-11-22 Fluorinated or hydroxylated phenylimidazolidines, preparation process and intermediates, use as medicaments, new use and pharmaceutical compositions.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9513836A FR2741342B1 (fr) 1995-11-22 1995-11-22 Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques

Publications (2)

Publication Number Publication Date
FR2741342A1 FR2741342A1 (fr) 1997-05-23
FR2741342B1 true FR2741342B1 (fr) 1998-02-06

Family

ID=9484799

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9513836A Expired - Fee Related FR2741342B1 (fr) 1995-11-22 1995-11-22 Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques

Country Status (7)

Country Link
US (1) US6087509A (fr)
EP (1) EP0862559A1 (fr)
JP (1) JP2000502053A (fr)
AU (1) AU7698496A (fr)
FR (1) FR2741342B1 (fr)
WO (1) WO1997019064A1 (fr)
ZA (1) ZA969820B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5162064B2 (ja) * 1998-10-23 2013-03-13 アベンティス・ファーマ・ソシエテ・アノニム 抗アンドロゲン作用を有する物質を局所適用するための処方物
HUP0402338A3 (en) * 2001-10-01 2008-10-28 Bristol Myers Squibb Co Spiro-hydantoin compounds, their use as anti-inflammatory agents, pharmaceutical compositions containing them and intermediates for preparing them
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
ATE502298T1 (de) * 2003-12-19 2011-04-15 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
AU2011202578B2 (en) * 2004-02-24 2012-03-22 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
AU2005280908A1 (en) 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
TW200616634A (en) * 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
US7186727B2 (en) * 2004-12-14 2007-03-06 Bristol-Myers Squibb Company Pyridyl-substituted spiro-hydantoin compounds and use thereof
US20060142319A1 (en) * 2004-12-14 2006-06-29 Bang-Chi Chen Pyridyl-substituted spiro-hydantoin crystalline forms and process
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2013200745B2 (en) * 2005-05-13 2015-11-05 The Regents Of The University Of California Diarylhydantoin compounds
AU2015246137B2 (en) * 2005-05-13 2017-06-15 The Regents Of The University Of California Diarylhydantoin compounds
NZ591119A (en) * 2005-05-13 2012-08-31 Univ California Use of diarylhydantoin compounds for treating specific cancers
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
PL2004181T6 (pl) 2006-03-27 2023-09-04 The Regents Of The University Of California Modulator receptorów androgenowych do leczenia raka prostaty i chorób powiązanych z receptorami androgenowymi
CA2648139A1 (fr) 2006-03-29 2007-11-08 The Regents Of The University Of California Composes de diarylthiohydantoine et leur utilisation dans le traitement de troubles d'hyperproliferation
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
CN101631779A (zh) * 2006-12-12 2010-01-20 先灵公司 含有三环系统的天冬氨酰蛋白酶抑制剂
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
WO2011029392A1 (fr) * 2009-09-10 2011-03-17 Youzhi Tong Antagonistes du récepteur des androgènes et leurs utilisations
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2683694B1 (fr) 2011-03-10 2016-04-27 Suzhou Kintor Pharmaceuticals, Inc. Antagonistes des récepteurs d'androgènes et leurs utilisations
ES2541295T3 (es) 2011-04-21 2015-07-17 Orion Corporation Carboxamidas que modulan el receptor de andrógenos
UY34646A (es) 2012-03-02 2013-10-31 Novartis Ag Compuestos de espirohidantoína y su uso como moduladores selectivos del receptor de andrógenos
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52270A (en) * 1975-06-18 1977-01-05 Nippon Soda Co Ltd Hydantoin germicides for agriculture and gardening
MC1220A1 (fr) * 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
EP0091596B1 (fr) * 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Hydantoins, préparation et application
US4473393A (en) * 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
US4958028A (en) * 1988-12-22 1990-09-18 Ici Americas Inc. Process for the preparation of 5-substituted-3-phenyl imidazolidine-2,4-diones
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions

Also Published As

Publication number Publication date
WO1997019064A1 (fr) 1997-05-29
US6087509A (en) 2000-07-11
EP0862559A1 (fr) 1998-09-09
FR2741342A1 (fr) 1997-05-23
ZA969820B (en) 1997-11-24
JP2000502053A (ja) 2000-02-22
AU7698496A (en) 1997-06-11

Similar Documents

Publication Publication Date Title
FR2741342B1 (fr) Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
FR2744449B1 (fr) Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
FR2737118B1 (fr) Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
FI973279A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
AU3080895A (en) Novel piperazides derived from arylpiperazine, processes for their preparation, their use as medicaments and pharmaceutical compositions comprising them
FR2705566B1 (fr) Nouvelles compositions pharmaceutiques.
DZ2074A1 (fr) Formulation nouvelle contenant de la paroxétine, et procédé pour sa préparation.
MA23395A1 (fr) Procede de preparation de nouvelles formulations
FR2744448B1 (fr) Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
FR2715402B1 (fr) Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2722210B1 (fr) Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
HUP9801880A3 (en) Novel cryptophycins, their use and pharmaceutical compositions containing them
DZ3041A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procédé pour sa préparation.
FR2751876B1 (fr) Utilisation d'un oligosaccharide comme immunomodulateur, composition dermato-cosmetique et methode de traitement cosmetique
FR2724663B1 (fr) Huile d'argan enrichie, procede de preparation et composition cosmetique la comprenant
FR2733420B1 (fr) Preparations pectiques utilisables comme support de medicament
MA23663A1 (fr) Procede de preparation de formulations pharmaceutiques
FR2700956B1 (fr) Composition cosmetique et pharmaceutique et procede pour sa preparation.
FI953956A (fi) 2,3-rengaskondensoidut 1,4-dihydropyridiinit, menetelmät niiden valmistamiseksi ja niiden käyttö lääkkeinä
EP0978517A3 (fr) Triszolopurines, procédé pour leur préparation et leur application comme médicaments
DZ1965A1 (fr) Composition pharmaceutique nouvelle.
MA23194A1 (fr) Procede pour la preparation de particules preparees a sec, particules preparees a sec ainsi obtenues et compositions pharmaceutiques contenant de telles particules .
FR2740774B1 (fr) Nouveaux derives d'imidazole n-benzyldioxole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
FR2730163B1 (fr) Nouvelle composition pharmaceutique contenant la trimebutine et son procede de preparation
KR970704417A (ko) 친유성 히드록시산, 그의 화장제 및 약제학적 용도 및 그의 제조 방법(lipophilic hydroxylated acid, cosmetic and pharmaceutical use thereof and method for preparing same)

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property
ST Notification of lapse

Effective date: 20080930